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Objective: Inhaled nitric oxide has been shown to reduce pulmonary vascular resistance in patients undergoing
cardiothoracic surgery, but it is limited by toxicity, the need for special monitoring, and cost. Inhaled prostacyclin
also decreases pulmonary artery pressure, is relatively free of toxicity, requires no specific monitoring, and is less
expensive. The objective of this study was to compare nitric oxide and prostacyclin in the treatment of pulmonary
hypertension, refractory hypoxemia, and right ventricular dysfunction in thoracic transplant recipients in a pro-
spective, randomized, crossover pilot trial.
Methods:Heart transplant and lung transplant recipients were randomized to nitric oxide or prostacyclin as initial
treatment, followed by a crossover to the other agent after 6 hours. Pulmonary vasodilators were initiated in the
operating room for pulmonary hypertension, refractory hypoxemia, or right ventricular dysfunction. Nitric oxide
was administered at 20 ppm, and prostacyclin was administered at 20,000 ng/mL. Hemodynamic and oxygena-
tion parameters were recorded before and after initiation of pulmonary vasodilator therapy. At 6 hours, the hemo-
dynamic and oxygenation parameters were recorded again, just before discontinuing the initial agent. Crossover
baseline parameters were measured 30 minutes after the initial agent had been stopped. The crossover agent was
then started, and the hemodynamic and oxygenation parameters were measured again 30 minutes later.
Results: Heart transplant and lung transplant recipients (n ¼ 25) were randomized by initial treatment (nitric ox-
ide, n¼ 14; prostacyclin, n¼ 11). Nitric oxide and prostacyclin both reduced pulmonary artery pressure and cen-
tral venous pressure, and improved cardiac index and mixed venous oxygen saturation on initiation of therapy.
More importantly, at the 6-hour crossover trial, there were no significant differences between nitric oxide and
prostacyclin in the reduction of pulmonary artery pressures or central venous pressure, or in improvement in
cardiac index or mixed venous oxygen saturation. Nitric oxide and prostacyclin did not affect the oxygenation
index or systemic blood pressure. There were no complications associated with nitric oxide or prostacyclin.
Conclusion: In heart transplant and lung transplant recipients, nitric oxide and prostacyclin similarly reduce pul-
monary artery pressures and central venous pressure, and improve cardiac index and mixed venous oxygen sat-
uration. Inhaled prostacyclin may offer an alternative to nitric oxide in the treatment of pulmonary hypertension in
thoracic transplantation. (J Thorac Cardiovasc Surg 2009;138:1417-24)
CARDIOTHORACIC TRANSPLANTATIONT
XIn heart transplantation, donor heart right ventricular (RV)
dysfunction remains a major cause of early mortality.1,2
Elevated recipient pulmonary vascular resistance caused
by chronic left-sided heart failure, adverse effects of cardio-
pulmonary bypass and protamine, and donor heart ische-
mia-reperfusion injury contribute to the donor heart RV
dysfunction. Treatment strategies include optimization of
hemodynamic, acid-base, and oxygenation status, and
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doi:10.1016/j.jtcvs.2009.04.063The Journal of Thoracic and Cselective pulmonary vasodilator therapy. Similarly, primary
graft dysfunction (PGD) remains a major obstacle in lung
transplantation; it is a known risk factor for early and late
death, and the development of bronchiolitis obliterans syn-
drome.3,4 PGD is characterized by pulmonary hypertension
and hypoxemia. The standard treatment for PGD remains
supportive therapy. Selective pulmonary vasodilator ther-
apy is usually added to reduce pulmonary vascular resis-
tance and improve oxygenation.
Despite its off-label use, inhaled nitric oxide (NO) has be-
come a preferred agent in the management of pulmonary hy-
pertension, RV dysfunction, and refractory hypoxemia in
clinical heart and lung transplantation.5-9 Inhaled NO re-
quires a special delivery device, is associated with toxicities
that necessitate frequent monitoring, and is expensive.10 Be-
cause of these limitations of NO, several other agents have
been examined as alternatives. Inhaled prostacyclin (PGI2)
was first reported as a selective pulmonary vasodilator inardiovascular Surgery c Volume 138, Number 6 1417
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Xan experimentalmodel in 1993.11 PGI2 is an arachidonic acid
derivative with a half-life of 3 to 6 minutes. PGI2 binds to
a prostanoid receptor, causing an increase in intracellular
cyclic adenosine monophosphate and consequently vaso-
dilation. Inhaled PGI2 has been shown to reduce pulmonary
artery (PA) pressure and improve RV dysfunction and hyp-
oxemia in a variety of pathologic states.12-16 To the best of
our knowledge, there are no comparison studies of inhaled
PGI2 versus inhaled NO in heart transplant and lung trans-
plant recipients. The objective of this study was to compare
the efficacy of NO with PGI2 in heart transplant and lung
transplant recipients with pulmonary hypertension, RV dys-
function, or refractory hypoxemia. The primary end point of
this pilot trial was the mean PA pressure. The secondary end
points were central venous pressure (CVP), cardiac index,
mixed venous oxygen saturation (SvO2), mean systemic arte-
rial pressure, and oxygenation index (arterial oxygen tension
[PaO2]/inspired oxygen fraction [FIO2] ratio).
MATERIALS AND METHODS
This study was approved by the University of California Los Angeles In-
stitutional Review Board. All adult patients undergoing heart and lung
transplantation at the University of California Los Angeles were invited
to enroll in this study preoperatively.
In heart transplant recipients, the decision to institute pulmonary vasodi-
lator therapy was made by the attending surgeons at weaning of cardiopul-
monary bypass. The criteria included a) pulmonary hypertension defined as
mean PA pressure greater than 25 mm Hg or 2) RV dysfunction defined as
CVP greater than 12 mm Hg with cardiac index less than 2.2 L/min/m2 and
visual evidence of RV dysfunction. The standard inotropic regimen for
weaning heart transplant recipients off cardiopulmonary bypass included
epinephrine and milrinone. Pulmonary vasodilator therapy was instituted
once all other hemodynamic and metabolic parameters were optimized.
Patients were then randomized to NO or PGI2.
In single-lung transplant recipients, the decision to institute pulmonary
vasodilator therapy was made at the time of clamping the PA intraopera-
tively or anytime thereafter. Development of pulmonary hypertension
(defined as mean PA pressure >25 mm Hg) or hypoxemia (PaO2/FIO2
<150) prompted randomization to NO or PGI2. All double-lung transplant
procedures were performed with the assistance of cardiopulmonary bypass.
The decision to start pulmonary vasodilator therapy in double-lung trans-
plant recipients was made at the time of weaning of cardiopulmonary
Abbreviations and Acronyms
CI ¼ confidence interval
CVP ¼ central venous pressure
FIO2 ¼ inspired oxygen fraction
NO ¼ nitric oxide
PA ¼ pulmonary artery
PaO2 ¼ arterial oxygen tension
PGD ¼ primary graft dysfunction
PGI2 ¼ prostacyclin
RV ¼ right ventricular
SvO2 ¼ venous oxygen saturation1418 The Journal of Thoracic and Cardiovascular Sbypass, in the setting of pulmonary hypertension or hypoxemia, as
defined above.
Experimental Protocol
Once the decision was made to start pulmonary vasodilator therapy, the
patient was randomized to either NO (at 20 ppm) or PGI2 (at 20,000 ng/
mL). After 6 hours, the randomized agent was stopped for 30 minutes for
washout, and the crossover agent was begun (Figure 1). The rationale for
the 6-hour crossover trial was to allow sufficient time for the patient’s he-
modynamic and oxygenation parameters to stabilize. The crossover agent
was administered for 30 minutes, followed by switching to the originally
randomized agent. The duration of treatment and the weaning protocol
was determined by the clinical team. Hemodynamic and oxygenation pa-
rameters were collected at time 0 (before starting the randomized agent),
at 30 minutes (after starting the agent), at 6 hours (just before stopping
the randomized agent), at 6:30 hours (30 minutes after stopping therapy
[crossover baseline]), and at 7:00 hours (30 minutes after starting the cross-
over agent) (Figure 1). After recording of the hemodynamic and oxygena-
tion parameters, the originally randomized agent was re-started and
continued or weaned per clinicians’ decision. The collected hemodynamic
parameters included systemic arterial pressure (systolic, diastolic, and
mean), PA pressure (systolic, diastolic, and mean), CVP, cardiac index,
SvO2, and heart rate (unless paced). Oxygenation parameters included PO2,
FIO2, and oxygen saturation. All adverse events (methemoglobinemia, hypo-
tension [>30% decrease in mean blood pressure, unrelated to other mea-
sures], nonsurgical bleeding requiring reexploration, and complications of
the delivery system [ie, sticking of the ventilator valve]) were prospectively
recorded.
Studied Agents
NO was delivered from a tank at a concentration of 10,000 ppm diluted
in nitrogen (Ikaria, Clinton, NJ). The desired concentrationwas regulated by
a calibrated flow meter (Ikaria) and then delivered into the inspiratory limb
of the ventilator. Peak inspired NO and NO2 concentrations were continu-
ously analyzed by chemiluminescence (Ikaria). Exhaust gas was scavenged
via a soda-lime absorber. Methemoglobin concentration (as a percentage of
total hemoglobin) was measured at 6-hour intervals or more frequently if
clinically indicated.
PGI2 (Flolan, Glaxo Wellcare Inc, Research Triangle Park, NC) was re-
constituted in glycine buffer diluent to a final concentration of 20,000 ng/
mL by the pharmacy service and then delivered to the Respiratory Care Ser-
vice. The nebulizer chamber was initially primed with 15 mL of PGI2 solu-
tion, and then a 60-mL syringe of PGI2was attached to an intravenous pump
to be delivered at a rate of 8 mL/h to the nebulizer chamber. The nebulizer
system (Mini HEART nebulizer, Westmed, Tucson, AZ) was attached to
the inspiratory limb of the ventilator circuit. At an oxygen flow rate of
FIGURE 1. Time line for the experimental protocol and data collection.
Patients were randomized to a pulmonary vasodilator, shown as Agent A,
which was continued for 6 hours. Agent A was then stopped for 30 minutes
for washout. Next, the crossover agent, shown as Agent B, was started and
continued for 30 minutes. Therapy was then switched back to agent A,
which was continued or weaned per the clinicians’ decision. Time points
(arrows) for collection of hemodynamic and oxygenation parameters.urgery c December 2009
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X2 to 3 L/min, approximately 8 mL of PGI2 was nebulized per hour.
A respiratory therapist familiar with the system was readily available during
administration of PGI2.
Statistical Analysis
All data are presented as mean standard error of the mean, unless oth-
erwise indicated. Statistical analyses of the changes in hemodynamic and
oxygenation parameters were performed using paired t tests. By assuming
a minimal detectable difference in mean PA pressure between the 2 treat-
ment arms of at least 4 mm Hg, a patient standard deviation of 4 mm Hg,
and a significance level of .05, a minimum of 24 patients are necessary to
detect a difference, with more than 90% power.
RESULTS
Demographic and Clinical Data
The demographic and clinical data are presented in Table 1.
Thoracic transplant recipients (n ¼ 32) were randomized by
initial treatment. Of the 32 randomized patients, 25 were in-
cluded in the study (Figure 2). The 7 patients who were ex-
cluded failed to complete the study protocol; 6 patients (3
received NO and 3 received PGI2) were taken off the pulmo-
nary vasodilator because of early clinical improvement, and 1
patient in the PGI2 group became hemodynamically unstable
because ofmediastinal bleeding after heart transplantation and
the agent was discontinued. Reexploration revealed a surgical
bleeding site. Therapywas switched to the other agent at cross-
over in all 25 study patients, so each patient received both NO
and PGI2, and randomization determined only which agent
was started first. The inhaled pulmonary vasodilator therapy
was initiated for pulmonary hypertension in all patients (n ¼
25), with some patients also having refractory hypoxemia or
RV dysfunction (Table 1).
Nitric Oxide and Inhaled Prostacyclin Are Effective
in Improving Hemodynamics (at Initiation of
Therapy)
The hemodynamic data for the study patients before any
inhaled pulmonary vasodilator (0 minutes) are presented for
the cohort first treated with NO (n ¼ 14) or PGI2 (n ¼ 11)
in Table 2. The initial responses to the pulmonary vasodi-
lators after 30 minutes also are shown. NO and PGI2 treat-
ments resulted in significant reductions in PA pressures and
in CVP, increased cardiac index, and improved SvO2 after
30 minutes. Both agents showed no significant effects on
PaO2/FIO2 ratio or systemic arterial blood pressure after 30
minutes.
Nitric Oxide and Prostacyclin Similarly Reduce
Postoperative Pulmonary Artery Pressures
(at 6-Hour Crossover Trial)
As noted in the ‘‘Materials and Methods’’ section, the he-
modynamic and oxygenation parameters were measured af-
ter 6 hours of therapy with the initially randomized agent,
after 30 minutes of washout (crossover baseline), and after
30 minutes of therapy with the crossover agent (Figure 1).The Journal of Thoracic and CDuring the postoperative crossover protocol, NO and
PGI2 resulted in significant reductions in PA pressures com-
pared with the crossover baseline (Figure 3, A). NO de-
creased the systolic PA pressure (NO: 30  1 vs crossover
baseline: 46  2 mm Hg, P< .01), diastolic PA pressure
(NO: 17  1 vs crossover baseline: 25  1 mm Hg, P<
.01), and PA mean pressure (NO: 23  1 vs crossover base-
line: 34  1 mm Hg, P< .01). PGI2 treatment also reduced
the systolic PA pressure (NO: 28  1 vs crossover baseline:
46 2 mm Hg, P<.01), diastolic PA pressure (NO: 16 1
vs crossover baseline: 25  1 mm Hg, P< .01), and mean
PA pressure (NO: 22  1 vs crossover baseline: 34  1
mm Hg, P< .01).
More important, when inhaled NO and PGI2 were com-
pared, they had similar effects on PA pressure reduction at 6
hours. When the magnitude of the differences between the
PA pressures and the crossover baseline (D PA pressure ¼
PA pressurebaseline) were compared, the D PA pressures
for NO and PGI2 were similar (Figure 3, B). For NO and
PGI2, the D systolic PA pressures were 16  2 mm Hg
(95% confidence interval [CI], 11–20) and 17  2 mm Hg
(95% CI, 13–22), respectively (P ¼ .10). The D diastolic
PA pressures for NO and PGI2 were 8  1 mm Hg (95%
CI, 6–11) and 9  1 mm Hg (95% CI, 7–12), respectively
(P ¼ .12). The D mean PA pressures for NO and PGI2 were
12  1 mm Hg (95% CI, 9–15) and 13  1 mm Hg (95%
CI, 9–16), respectively (P ¼ .32).
Nitric Oxide and Prostacyclin Also Similarly
Decrease Central Venous Pressure, Increase Cardiac
Index, and Improve Mixed Venous Oxygen
Saturation (at 6-Hour Crossover Trial)
During the postoperative crossover protocol, both NO and
PGI2 significantly improved the hemodynamics compared
TABLE 1. Demographic and clinical data
Study group 25 patients
Groups randomized by initial treatment
NO 14 patients
PGI2 11 patients
Age (y) 59  2
Gender
Male 20
Female 5
Procedure
Single-lung transplant 17
Double-lung transplant 2
Orthotopic heart transplant 6
Indication for pulmonary vasodilator treatmenta
Pulmonary hypertension 25
Refractory hypoxemia 5
RV dysfunction 6
NO, Nitric oxide; PGI2, prostacyclin; RV, right ventricular. aMore than 1 indication
was present for some patients.ardiovascular Surgery c Volume 138, Number 6 1419
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XFIGURE 2. Flow diagram depicting the outcome of all screened and enrolled patients. NO, Nitric oxide; PGI2, prostacyclin.with the crossover baseline (Figure 4). NO and PGI2 de-
creased the CVP (NO: 10  1 vs crossover baseline: 14 
1 mm Hg, P< .01; PGI2: 9  1 vs crossover baseline: 14
 1 mm Hg, P< .01). NO and PGI2 also increased the car-
diac index (NO: 3.0  0.1 vs crossover baseline: 2.5  0.1
L/min/m2, P< .01; PGI2: 3.1  0.2 vs crossover baseline:
2.5 0.1 L/min/m2, P<.01) and SvO2 (NO: 72 2 vs cross-
over baseline: 66 1%, P<.01; PGI2: 71 2 vs crossover
baseline: 66%  1%, P< .01).
Moreover, when the magnitude of the differences be-
tween the hemodynamic values and the crossover baseline
values were determined (eg, D CVP ¼ CVP  baseline),
the D hemodynamic results were comparable. For NO and
PGI2, the D CVP values were 4  1 mm Hg (95% CI,
3–5) and 5  1 mm Hg (95% CI, 3–6), respectively (P ¼
.36). The D cardiac index values were 0.6  .01 L/min/m2
(95% CI, 0.4–0.9) and 0.8  0.1 L/min/m2 (95% CI, 0.5–
1.1), respectively (P ¼ .40). Finally, the D SvO2 values
were 7%  1% (95% CI, 4–9) and 7%  1% (95% CI,
4–10), respectively (P ¼ .91).1420 The Journal of Thoracic and Cardiovascular SNitric Oxide and Prostacyclin Treatments
Demonstrate No Significant Alterations in
Postoperative Oxygenation or Systemic Arterial
Blood Pressure (at 6-Hour Crossover Trial)
During the postoperative crossover protocol, NO showed
no significant reduction in systemic arterial blood pressures
(systolic: 104  3 vs crossover baseline: 102  3 mm Hg,
P ¼ .46; diastolic: 58  2 vs crossover baseline: 57  2 mm
Hg, P ¼ .30; and mean: 73  2 vs crossover baseline: 72 
2 mm Hg, P ¼ .62). PGI2 also resulted in no significant de-
crease in systemic blood pressure (systolic: 99  3 vs cross-
over baseline: 102  3 mm Hg, P ¼ .24; diastolic: 55  2
vs crossover baseline: 57  2 mm Hg, P ¼ .13; and mean:
71  2 vs crossover baseline: 72  3 mm Hg, P ¼ .63). NO
and PGI2 did not improve the PaO2/FIO2 ratio compared with
the crossover baseline (NO: 269  25 vs crossover baseline:
250  24, P ¼ .06; PGI2: 256  27 vs crossover baseline:
250  24, P ¼ .77). In addition, there were no differences in
PaO2/FIO2 ratio or systemic blood pressures when NO was
compared with PGI2 (all P ¼ not significant, NO vs PGI2).urgery c December 2009
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The 30-day survival of this cohort of patients was 100%.
The median intensive care unit stay was 3 days. None of the
25 patients who completed this study required reexploration
for bleeding. None of the heart transplant recipients required
augmentation of therapy for pulmonary hypertension or RV
dysfunction (ie, insertion of intra-aortic balloon pump, open-
ing of the chest, or insertion of RV assist device). The inci-
dence of PGD (grade 3) among lung transplant recipients at
48 hours was 5.3%. There were no complications related
to the PGI2 delivery system or PGI2 (systemic hypotension,
flushing, nonsurgical bleeding), and we did not observe any
toxicity related to NO administration (methemoglobinemia).
DISCUSSION
This study demonstrates that inhaled NO and PGI2 are
equally effective in reducing the PA pressure and CVP, and
increasing cardiac index and SvO2 at a crossover trial in a co-
hort of heart transplant and lung transplant recipients. More-
over, there were no complications of the PGI2 delivery
system or toxicity associated to either agent during this study.
An additional finding of this study is that in heart and lung
transplant recipients with pulmonary hypertension, NO and
inhaled PGI2 can reduce PApressures andCVP, and improve
cardiac index and SvO2 immediately after initiation of ther-
apy. This latter observation is consistentwith previous reports
showing that inhaled NO improves pulmonary hemodynam-
ics and oxygenation in thoracic transplant recipients.5-9
Inhaled PGI2 has also been demonstrated to be an effec-
tive treatment for pulmonary hypertension, RV dysfunction,
and hypoxemia in cardiothoracic surgery.12,14 Haraldsson
and colleagues12 reported the efficacy of inhaled PGI2 in
producing a dose-dependent decrease in PVR, transpulmo-
nary gradient, and CVP after cardiac surgery or heart trans-
TABLE 2. Initial response to nitric oxide and prostacyclin was similar
NO
(n ¼ 14)
PGI2
(n ¼ 11)
0 min 30 min 0 min 30 min
PA systolic (mm Hg) 43  2 36  2a 51  2 38  2a
PA diastolic (mm Hg) 24  1 19  1a 27  3 21  2a
PA mean (mm Hg) 32  1 26  1a 37  3 28  3a
CVP (mm Hg) 14  1 11  1a 14  1 10  1a
Cardiac
index (L/min/m2)
2.5  0.2 3.0  0.3a 2.6  0.2 3.0  0.9a
SvO2 (%) 69  3 77  2a 71  2 76  3a
PaO2/FIO2 ratio 295  42 330  35 304  51 360  59
BP systolic (mm Hg) 97  3 88  3 95  4 95  3
BP diastolic (mm Hg) 59  2 56  4 57  3 55  3
BP mean (mm Hg) 72  3 66  3 71  3 69  3
BP,Blood pressure; PA, pulmonary artery;CVP, central venous pressure; SvO2,mixed
venous blood O2 saturation; NO, nitric oxide; PGI2, prostacyclin. NO and PGI2 sig-
nificantly decreased PA pressures and CVP, increased CI, and improved SvO2 after 30
minutes. No significant differences were observed in PaO2/FIO2 ratio or systemic blood
pressures. aP< .05 versus 0 minutes.The Journal of Thoracic and Cplantation. In lung transplantation, inhaled PGI2 has been
described as an effective alternative to NO in the treatment
of pulmonary hypertension.14 Moreover, a prospective co-
hort study of 126 consecutive patients who underwent car-
diothoracic surgery, including 12 heart and 43 lung
transplant recipients, investigated the use of inhaled PGI2.
Patients in this study with a mean PA pressure greater than
30 mm Hg, PaO2/FIO2 ratio less than 150, or CVP greater
than 16 mm Hg with a cardiac index less than 2.2 L/min/
m2 were treated with inhaled PGI2. In this cohort analysis,
inhaled PGI2 decreased PA pressures, increased oxygena-
tion, and improved RV function.17
The central message from this report is that inhaled NO
and PGI2 are equivalent in their hemodynamic effects at 6
hours after initiation of therapy in heart transplant and
lung transplant recipients. Considering the findings of this
comparison study and prior reports noted above, there is
now growing evidence for the use of inhaled PGI2 as an al-
ternative agent to NO in the treatment of pulmonary hyper-
tension in thoracic transplantation. Inhaled PGI2 offers
several advantages over NO that include a relative lack of
FIGURE 3. NO and PGI2 similarly reduce PA pressures at the 6-hour
crossover trial. NO and PGI2 showed significant reductions in systolic,
diastolic, and mean PA pressures compared with crossover baseline
(*P< .01). NO, Nitric oxide; PA, pulmonary artery; PGI2, prostacyclin.ardiovascular Surgery c Volume 138, Number 6 1421
Cardiothoracic Transplantation Khan et al
T
Xtoxicity and ease of delivery. NO requires specialized deliv-
ery systems and has known toxicities, such as methemoglo-
binemia, which limit the utility of the agent.10,18 However,
toxicity caused by methemoglobinemia was not seen in
FIGURE 4. NO and PGI2 similarly improve hemodynamics at the 6-hour
crossover trial. NO and PGI2 therapy decreased CVP and improved cardiac
index and SvO2 when compared with crossover baseline values (*P< .01).
NO, Nitric oxide; PGI2, prostacyclin; SvO2, venous oxygen saturation.1422 The Journal of Thoracic and Cardiovascular Suthis study. Another benefit is that PGI2 is less expensive
than NO.
Although PGI2 offers a potentially less toxic, cheaper al-
ternative to NO, there are disadvantages of PGI2. Systemic
hypotension and flushing have been associated with inhaled
PGI2, although these side effects were not observed in our
study. Another concern is the risk of bleeding with inhaled
PGI2 therapy, potentially related to platelet inhibition.19
One patient who was initially randomized to inhaled PGI2
was taken off the drug immediately and excluded from the
study with the development of hypotension caused by surgi-
cal bleeding. There was no indication that the bleeding was
due to inhaled PGI2 administration. In a prospective, dou-
ble-blind, randomized study of 28 patients undergoing elec-
tive cardiac surgery, inhaled PGI2 resulted in impaired
platelet function in vitro; however, there was no significant
difference in chest tube output or hematocrit between control
and treatment groups.20 Finally, there are technical issues in-
volving the nebulizer delivery system and the mechanical
ventilator. An inadvertent bolus of PGI2 as the result of tip-
ping of the nebulizer is possible, which is a particular concern
during transport from the operating room to the intensive care
unit. Because of the sticky nature of the buffering agent, there
is a danger of sticking of the ventilator valves, which is pre-
vented by the required frequent changing of filters. During
this study, no technical complications with the delivery of in-
haled PGI2 or mechanical ventilator valves occurred. During
inhaled PGI2 treatment, the availability of a respiratory ther-
apist is required to monitor the nebulizer delivery system and
ventilator, as well as frequently change the ventilator filters.
Although this study demonstrates that inhaled NO and
PGI2 are equally effective in reducing PA pressures and im-
proving other hemodynamic parameters, there was no signif-
icant improvement in oxygenation, as reported by several
prior studies.7,8,21 One factor that may explain these findings
is that only 5 of the 25 patients in this study had a PaO2/FIO2
ratio less than 150. The mean PaO2/FIO2 ratio at the crossover
baseline was 250. In the 5 patients who had a PaO2/FIO2 ratio
less than 150, there was an approximately 50% increase in
the PaO2/FIO2 ratio for both NO and PGI2 therapy. A larger
number of patients with hypoxemiamay have shown a statis-
tically significant effect on oxygenation in this study.
A potential concern at the inception of this study was the
rebound pulmonary hypertension at the crossover period.
Although the PA pressures increased in nearly all patients
at the time of crossover, none became hemodynamically un-
stable. In patients with difficulty weaning from NO, sildena-
fil has been shown to reduce PA pressures and allow
weaning from the inhaled pulmonary vasodilator ther-
apy.22,23 Sildenafil, a phosphodiesterase type 5 inhibitor, is
an oral pulmonary vasodilator that prevents the breakdown
of cGMP.24,25 Sildenafil was used liberally in this cohort
of patients to facilitate weaning from NO or inhaled PGI2,
after completion of the study.rgery c December 2009
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There are several limitations of this study that deserve
mention. a) There were many confounding variables that
may have affected the oxygenation and hemodynamic pa-
rameters. These variables may have included the intraoper-
ative and postoperative management of the ventilator,
inotropic agents, vasodilators, and organ function. The man-
agement of these aspects of care was left under the control of
the clinicians in the operating room and the intensive care
unit. The optimization of the intraoperative and postopera-
tive care directly by the clinicians was the safest way to per-
form the study without sacrificing patient care. b) Another
limitation was the timing of the study. Our direct crossover
comparison of NO and PGI2 was performed during the post-
operative period, 6 hours after starting inhaled pulmonary
vasodilator therapy. Because of the relative instability of
thoracic transplant recipients in the operating room com-
pared with 6 hours later, a crossover of agents at 30 minutes
was not considered a safe experimental protocol. c) Another
limitation of this study is the small number of studied sub-
jects (especially heart transplant recipients). d) The findings
of this study are only applicable to heart transplant and lung
transplant recipients with ‘‘moderate’’ pulmonary hyperten-
sion, in the early postoperative periods. Caution needs to be
exercised in the application of these findings to other patient
populations (eg, adult patients undergoing cardiac surgery or
pediatric patients). e) Finally, with the nebulizer method of
drug delivery for inhaled PGI2, the exact amount of agent
that reaches the alveoli is uncertain because of losses in
the nebulizer chamber and ventilator tubing, and may vary
in each patient (eg, depending on the mode of ventilation,
settings, temperature).12
CONCLUSIONS
This prospective, randomized, crossover pilot study of in-
haled pulmonary vasodilators in thoracic transplant recipi-
ents demonstrates that NO and inhaled PGI2 provide
equivalent reductions in PA pressures and improvements
in other hemodynamic parameters. Therefore, PGI2 may of-
fer an alternative to NO in the treatment of pulmonary hyper-
tension in thoracic transplantation.
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XDiscussion
DrMichael Mulligan (Seattle, Wash). I would like to thank the
association for inviting me to discuss this paper and Dr Khan and
his colleagues for sending me the manuscript in advance. Congrat-
ulations on a fine presentation and for conducting a prospective ran-
domized trial in an attempt to answer a timely question. You added
50%more patients between submission of the abstract and the man-
uscript, so I paid attention and I think I understand your take-home
message but let’s work through this.
I have 2 comments and then 3 questions.
The first comment is that you combined heart and lung transplant
patients and I do not think that is appropriate. That is apples and or-
anges, and I think you think so, too, because you use different en-
trance criteria to include heart or lung transplant recipients.
Whereas pulmonary artery pressures and elevations in pulmonary
vascular resistance have obvious implications for outcomes in heart
transplant patients with right ventricular dysfunction, elevated pul-
monary artery pressures are not even used in the grading criteria for
primary graft dysfunction after lung transplantation. Rather, we use
P to F ratios and infiltrates.
Second comment—you raised 3 concerns about inhaled nitric
oxide: the need for complex delivery systems, potential toxicities,
and cost. Yet in your data and in your discussion, you realize that
both inhaled nitric oxide and nebulized prostacyclin require some-
what complex delivery systems and you observed no toxicity so it
really comes down to cost. If we have already spent so much, on
a lung transplantation for example, I think it is best to use the
best drug with the best bioavailability in the alveolar space with
the best effect on ventilation perfusion matching, accepting an in-
crease in cost that is real but only a small fraction of the overall
price of the successful patient outcome. Ultimately, we still do
not appear to know which agent is best.
I will move on to the questions.
First question, there were 17 patients in the abstract and 25 pa-
tients in the manuscript. The numbers are really too small to
draw any definitive conclusions about efficacy in heart transplant
recipients or in lung transplant recipients. Was this your target or
did you stop enrollment early for some reason?
Dr Khan. We initially had a target of 100 patients. However,
when we did our preliminary analysis and reviewed this with
______ we found reasonable data that we concluded the study
early.
DrMulligan. I would challenge the fact that you hit a home run
because hypoxia is—this is my second question. Hypoxia is the un-1424 The Journal of Thoracic and Cardiovascular Sdoing of a lung transplant recipient in primary graft dysfunction;
yet, in your manuscript you showed no improvement in P to F ratios
with either nebulized prostacyclin or inhaled nitric oxide. Many
other studies have shown beneficial effects with both. This is espe-
cially true with inhaled nitric oxide, presumably related to the better
alveolar distribution of a gas as compared with a nebulized solu-
tion. Why do you suppose that in your study you did not see any
improvement in P to F ratios? Did it have something to do with
the 8 additional patients added, because in your abstract you did
see a benefit, or was it because you simply did not have enough
acute graft dysfunction in lung transplant population?
DrKhan. The difference between the data in the abstract and the
manuscript with the larger numbers, the small difference in im-
provement in PF ratio became no longer significant. That was be-
cause in the group of patients that had a PF ratio of less than 200,
when you looked at that subgroup, they had approximately 50% in-
crease in PF ratio because their PF ratio started in the 50–100 range.
However, when you look at the mean of the whole group, the aver-
age is 200–250.When we did look at that group separately, they did
have an improvement in oxygenation from both agents. However,
when we added more patients, none of whom had hypoxia, it di-
luted out that finding.
DrMulligan. I think that gets back to the original comment that
we probably should not mix heart and lung transplant patients to-
gether in such a study and we should expand it to include more
lung transplant patients.
The last question is that in your manuscript and in your presen-
tation you talked about a 5.3% incidence of grade III primary graft
dysfunction in your lung recipients, yet 5 of 17 or 5 of 25 had P to
F ratios of less than 200, which would imply a grade III primary
graft dysfunction if they were lung transplant recipients. What
was your actual incidence of primary graft dysfunction in this
population?
Dr Khan. It was 5.3% at 48 hours. However, that initial data of
the 5 patients who had hypoxemia initially was at the time of
randomization in the operating room, so several of these patients
improved during the next 48 hours such that there was only 1
patient remaining who met the criteria.
DrMulligan. There is an upfront and then there is a delayed as-
sessment, so I do not know which one is valid but it appeared to be
disparate between your early and late assessments.
Again congratulations and I appreciate the opportunity to dis-
cuss the paper.
Dr Khan. Thank you.urgery c December 2009
